Crispr Therapeutics AG
$ 52.45
-1.17%
05 Aug - close price
- Market Cap 5,131,479,000 USD
- Current Price $ 52.45
- High / Low $ 53.33 / 51.81
- Stock P/E N/A
- Book Value 18.83
- EPS -6.61
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.14 %
- ROE -0.31 %
- 52 Week High 78.48
- 52 Week Low 44.12
About
CRISPR Therapeutics AG, a gene editing company, focuses on the development of gene-based transformative drugs for serious human diseases. The company is headquartered in Zug, Switzerland.
Analyst Target Price
$87.22
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-03 | 2026-05-04 | 2026-02-12 | 2025-11-10 | 2025-08-04 | 2025-05-06 | 2025-02-11 | 2024-11-05 | 2024-08-05 | 2024-05-08 | 2024-02-21 | 2023-11-06 |
| Reported EPS | -0.94 | -1.28 | -1.37 | -1.17 | -1.29 | -1.58 | -0.44 | -1.01 | -1.49 | -1.43 | 1.1 | -1.41 |
| Estimated EPS | -1.1 | -1.23 | -1.23 | -1.29 | -1.4 | -1.28 | -1.1856 | -1.4 | -1.43 | -1.33 | 0.05 | -1.95 |
| Surprise | 0.16 | -0.05 | -0.14 | 0.12 | 0.11 | -0.3 | 0.7456 | 0.39 | -0.06 | -0.1 | 1.05 | 0.54 |
| Surprise Percentage | 14.5455% | -4.065% | -11.3821% | 9.3023% | 7.8571% | -23.4375% | 62.888% | 27.8571% | -4.1958% | -7.5188% | 2100% | 27.6923% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CRSP
2026-08-05 04:15:20
CRISPR Therapeutics (CRSP) saw its stock rise by 11.6% following positive Q2 2026 results, which included an increase in revenue, a shrinking net loss, and the expansion of CASGEVY's FDA approval to younger children. The company also announced new in vivo trials across cardiovascular, autoimmune, and oncology indications, strengthening its gene-editing pipeline. Despite these positive developments, the company remains loss-making, and investors hold varied opinions on its fair value, highlighting ongoing uncertainties regarding commercial adoption and clinical success.
2026-08-04 15:10:38
CRISPR Therapeutics (CRSP) reported a narrower-than-expected loss of 94 cents per share for Q2 2026, surpassing the Zacks Consensus Estimate of a $1.10 loss. The company's total revenues also exceeded expectations, reaching $10.2 million against an estimate of $7 million, driven by strong collaboration revenue from Casgevy sales. Casgevy, developed with Vertex Pharmaceuticals, saw significant sales growth and expanded regulatory approvals, while CRISPR Therapeutics maintained a robust cash position and continues to advance a diverse clinical pipeline with multiple updates anticipated in the second half of 2026.
2026-08-04 14:56:00
CRISPR Therapeutics (CRSP) reported a narrower-than-expected loss of 94 cents per share in Q2 2026, surpassing the Zacks Consensus Estimate of a $1.10 loss. Total revenues reached $10.2 million, also exceeding the $7 million estimate, driven by strong collaboration revenue. The company's Casgevy gene therapy, developed with Vertex Pharmaceuticals, is showing robust sales momentum, while CRISPR Therapeutics continues to advance multiple candidates in its clinical pipeline.
2026-08-04 10:15:20
CRISPR Therapeutics reported strong Q2 2026 financial results, with CASGEVY revenue reaching $76 million, a 151% year-over-year increase. A significant highlight was the FDA's approval of CASGEVY for children as young as two years old with sickle cell disease or transfusion-dependent beta thalassemia, potentially making 5,500 more patients eligible. The company also advanced several other clinical programs and maintained a robust cash position of $2.36 billion.
2026-08-03 22:10:47
Crispr Therapeutics reported a second-quarter EPS of $-0.94, surpassing analyst estimates by $0.26, and revenue of $10.18M, which also topped the consensus estimate. Despite the strong earnings beat, the company's stock price has seen declines over the last three and twelve months. InvestingPro assesses Crispr Therapeutics' financial health as "fair performance."
2026-08-03 21:10:47
CRISPR Therapeutics (NASDAQ:CRSP) announced its quarterly earnings, reporting an adjusted loss of $0.94 per share, significantly beating analyst estimates of a $1.20 loss. The company also surpassed revenue expectations, bringing in $10.18 million against an estimated $7.45 million. Following these results, CRSP shares rose 3.3% to $49.57, although they remain below their 52-week high, and analysts maintain a "Moderate Buy" consensus with a target price of $67.78.
